Metabolic syndrome with the atypical antipsychotics

Abstract

More data have become available on the burden from metabolic complications associated with SGAs. New and effective treatment options are required in the near future to improve cardiovascular health in this susceptible population.

A Novel Aminotetralin-Type Serotonin (5-HT)2CReceptor-Specific Agonist and 5-HT2ACompetitive Antagonist/5-HT2BInverse Agonist with Preclinical Efficacy for Psychoses

“…Other serious side effects of especially second-generation antipsychotic drugs include metabolic syndrome-specifically high glucose and cholesterol (Pramyothin and Khaodhiar, 2010)-as well as increased appetite and weight gain leading to obesity (Stip et al, 2012). (2)-MBP, in contrast, suppressed feeding in a mouse model of compulsive binge-eating/snackfood intake, suggestive of 5-HT 2C agonism, which is known to decrease feeding and reduce weight in rodents and humans (Smith et al, 2010).…”

N-Aryl Piperazine Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators Possess Efficacy in Preclinical Models of NMDA Hypofunction and Cognitive Enhancement

“…Poor functional and social outcomes are directly correlated with the cognitive deficits observed in patients with schizophrenia (Wu et al, 2005;Green, 2006). Currently available typical and atypical antipsychotic therapies are effective in decreasing the psychotic symptoms, but provide little or no relief for the negative symptoms or cognitive impairments and are associated with multiple adverse side effects (Swartz et al, 2008;Adrianzen et al, 2010;Pramyothin and Khaodhiar, 2010). Accumulating evidence suggests that impaired transmission through glutamatergic circuits may contribute to all three major symptom clusters observed in patients with schizophrenia (Krystal et al, 2002;Lewis and Moghaddam, 2006).…”

Agomelatine Addressing Behavioural Facets in Autism

“…Both atypical antipsychotics, risperidone (Risperdal®) and aripiprazole (Abilify®) are currently FDA-approved to address these behavioural facets [3]. Nonetheless, these agents, along with other antipsychotics, are plagued with a myriad of adverse drug reactions, notably, the neurologic and cardio-metabolic syndromes [4]. This amply illustrates a pressing need to explore alternative agents that are both effective and tolerable.…”